TBC
TBC
Validation Strategies for Pharmaceutical Patents in Europe
Special Report
The decision on where to validate a pharmaceutical European patent is a big one. With costs often precluding an “everywhere” approach for small- to medium-sized companies, research institutions and universities, it is necessary to choose from the long list of available countries. The choice typically factors in costs, business interests, likely markets and market size, possible manufacturing and import locations and the regulatory framework in Europe.
This report explores these choices and factors using publicly available data, seeking to answer questions such as:
- Which countries are most commonly picked by patent holders at the EPO?
- Is the distribution the same for pharmaceutical patents?
- Where does “big pharma” choose to validate?
- What factors might affect the choice of countries?
Read our blogs
Most opposed companies at the EPO in 2024
Opposition activity at the European Patent Office is often a strong indicator of a technology’s commercial relevance. We analysed the companies holding the highest numbers of European patents that ...
Mewburn Ellis is proud to have worked on 24 of the 100 top-selling pharmaceuticals of 2024
Mewburn Ellis works with some of the world’s most important pharmaceuticals and biologics across a broad range of therapeutic areas.
Optimising Training for the Menstrual Cycle
In recent years, there's been a noticeable shift in how we approach female athletic performance, with increasing attention paid to the menstrual cycle and its impact on training outcomes. No longer a ...
Mewburn Ellis Extends BII Residency, Deepening Support for Denmark’s Innovation Ecosystem
Mewburn Ellis is pleased to announce that we have extended our residency at the BioInnovation Institute (BII) in Copenhagen for another two years — a decision that reinforces our long-standing ...
Most opposed patents of 2024
The list is, again, dominated by patents for therapeutic treatments, although the trends seen last year for patents on recycling and renewable technologies have continued (these are the green bars in ...
BluMaiden: Pioneering AI-Driven Precision in Immunotherapy Response Prediction
BluMaiden uses AI and microbiome insights to boost immunotherapy prediction and speed up drug discovery.
Mewburn Ellis
FORWARD MAGAZINE
Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.